AnaNeo Therapeutics personnel are using an FDA approved co-theragnostic precision medicine test to identify patients having a specific DNA repair deficiency and identifying candidate compounds to kill cancer cells carrying this DNA repair deficiency. These patients are currently being treated with "traditional" cytotoxic chemotherapy that is both difficult to tolerate and also is reported as having response rates that are defined overall as mediocre to poor. That moted, with all but one/two listed parties to Ananeo Therapeutics being primarily employed by the Memorial Sloan Kettering Cancer Center (MSKCC), the extent to which this project - if effective - could continue into Phase II may become an issue.
